As­traZeneca halts two PhI­II hy­per­kalemia stud­ies in­tend­ed to spot­light Lokel­ma’s clin­i­cal val­ue

As­traZeneca an­nounced ear­ly Fri­day morn­ing that it is stop­ping work on two late-stage tri­als de­signed to gath­er val­ue-added ev­i­dence for Lokel­ma in hy­per­kalemia, a chron­ic con­di­tion for which the drug is al­ready ap­proved.

The Phase III STA­BI­LIZE-CKD tri­al faced “sub­stan­tial­ly in­creased en­rol­ment time­lines,” while the Phase III DI­AL­IZE-Out­comes tri­al re­port­ed low event rates. As such, “it was pro­hib­i­tive to de­liv­er study re­sults with­in a time­frame to mean­ing­ful­ly ad­vance clin­i­cal prac­tice,” the com­pa­ny said in a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER